Equity Profile

FMS

Fresenius Medical Care AG

Health CareHealth Care Services$11.8B

May5Tue

Pre-Earnings Brief

UpcomingQ1-2026After Close9:00 AM EDT

Company Snapshot

Fresenius Medical Care AG (FMS) is a leading provider of products and services for individuals undergoing dialysis due to chronic kidney failure. Operating in the Health Care sector, the company plays a crucial role in managing the health of patients with kidney diseases, which is increasingly important as the global prevalence of such conditions rises.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$0.50

Revenue

Total revenue gives insight into the company's overall sales performance and market demand for its services.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius Medical Care reported an EPS of $0.17, falling short of the expected $0.18. The stock reacted negatively, declining by 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic, expecting Fresenius to report an EPS of $0.50 and revenue of $4.6 billion. However, given the company's recent performance, there is uncertainty about whether these targets will be met.

Bull Case

If Fresenius exceeds the EPS estimate, it could signal improved operational efficiency and patient demand, leading to a positive market reaction.

Bear Case

A miss on earnings or revenue could raise concerns about the company's ability to manage costs and maintain growth in a challenging health care environment.

Key Metrics to Watch

EPS

$0.50

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$4.6B

Total revenue gives insight into the company's overall sales performance and market demand for its services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.50?

A beat on EPS could indicate better-than-expected operational performance and may boost investor confidence.

What insights will management provide on revenue growth and patient demand?

Understanding revenue trends and demand can help investors gauge the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for Fresenius to leverage its existing patient base for increased revenue, especially in the context of rising chronic kidney disease rates.

Supporting Evidence

The company's historical ability to recover from earnings misses suggests it could outperform expectations this quarter.

Options pricing indicates a higher expected move than historical averages, suggesting that the market may be overly cautious.

Key Risk

If revenue growth exceeds $4.7B, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a disappointing Q1 2023, and investors are looking for signs of recovery.

Bull Confirmed If

An EPS of $0.53 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.47 would suggest ongoing challenges in profitability and could lead to negative sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that investors expect volatility.

Options are pricing ±4.4% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

22.1%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests the stock could see a modest increase, confirming improved operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience limited movement as investors await further clarity from management.

Miss

A miss on earnings could lead to a decline in stock price, with historical patterns indicating an average drop of around 1.23%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on patient enrollment and demand trends for dialysis services.
2Comments on cost management strategies and their impact on margins.
3Insights into competitive pressures and market share.
4Discussion of any new products or services that could drive future growth.
5Management's outlook on regulatory changes affecting the health care sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$0.50

Revenue

Total revenue gives insight into the company's overall sales performance and market demand for its services.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius Medical Care reported an EPS of $0.17, falling short of the expected $0.18. The stock reacted negatively, declining by 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Fresenius exceeds the EPS estimate, it could signal improved operational efficiency and patient demand, leading to a positive market reaction.

Bear Case

A miss on earnings or revenue could raise concerns about the company's ability to manage costs and maintain growth in a challenging health care environment.

Key Metrics to Watch

EPS

$0.50

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$4.6B

Total revenue gives insight into the company's overall sales performance and market demand for its services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.50?

A beat on EPS could indicate better-than-expected operational performance and may boost investor confidence.

What insights will management provide on revenue growth and patient demand?

Understanding revenue trends and demand can help investors gauge the company's market position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for Fresenius to leverage its existing patient base for increased revenue, especially in the context of rising chronic kidney disease rates.

Supporting Evidence

The company's historical ability to recover from earnings misses suggests it could outperform expectations this quarter.

Options pricing indicates a higher expected move than historical averages, suggesting that the market may be overly cautious.

Key Risk

If revenue growth exceeds $4.7B, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a disappointing Q1 2023, and investors are looking for signs of recovery.

Bull Confirmed If

An EPS of $0.53 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.47 would suggest ongoing challenges in profitability and could lead to negative sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that investors expect volatility.

Options are pricing ±4.4% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

22.1%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests the stock could see a modest increase, confirming improved operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience limited movement as investors await further clarity from management.

Miss

A miss on earnings could lead to a decline in stock price, with historical patterns indicating an average drop of around 1.23%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on patient enrollment and demand trends for dialysis services.
2Comments on cost management strategies and their impact on margins.
3Insights into competitive pressures and market share.
4Discussion of any new products or services that could drive future growth.
5Management's outlook on regulatory changes affecting the health care sector.